BridgeBio Pharma (BBIO) Assets Average (2018 - 2026)

BridgeBio Pharma (BBIO) has 9 years of Assets Average data on file, last reported at $1.2 billion in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 28.1% year-over-year to $1.2 billion; the trailing twelve-month figure through Mar 2026 stood at $1.2 billion (up 28.1% YoY), and the FY2025 full-year result was $927.7 million, up 26.58% from the prior year.
• Assets Average grew to $1.2 billion in Q1 2026, from $967.1 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $1.2 billion in Q1 2026 to a low of $564.7 million in Q2 2023.
• A 5-year average of $804.3 million and a median of $795.5 million in 2022 frame the typical range for Assets Average.
• Across the five-year window, Assets Average slumped 32.59% in 2023 and soared 45.55% in 2024, its largest moves.
• Tracing BBIO's Assets Average over 5 years: stood at $675.9 million in 2022, then decreased by 11.13% to $600.7 million in 2023, then jumped by 31.87% to $792.2 million in 2024, then increased by 22.09% to $967.1 million in 2025, then rose by 19.27% to $1.2 billion in 2026.
• Business Quant data shows BBIO's Assets Average at $1.2 billion in Q1 2026, $967.1 million in Q4 2025, and $1.0 billion in Q3 2025.